By dissecting the intricate PDGFRA-mediated signaling network, we highlight critical targets and outline strategies for developing precision-oriented, individualized immunotherapeutic interventions, aiming to significantly improve outcomes for patients with gliomas. This evidence concerns the gene PDGFRA and glioma.